Aliases & Classifications for Hypogonadism, Male

MalaCards integrated aliases for Hypogonadism, Male:

Name: Hypogonadism, Male 57
Male Hypogonadism 37 29
Testicular Hypogonadism 73
Hypogonadism Male 55

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
hypogonadism, male:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 241100
MedGen 42 C0151721
KEGG 37 H02027
UMLS 73 C0151721

Summaries for Hypogonadism, Male

OMIM : 57 Familial male hypogonadism is a highly heterogeneous category from which some disorders such as Reifenstein syndrome (312300), Kallmann syndrome (see 308700), isolated gonadotropin deficiency, and some other entities can be separated. The presence of an autosomal recessive form is suggested by the occurrence of parental consanguinity (Nowakowski and Lenz, 1961). (241100)

MalaCards based summary : Hypogonadism, Male, also known as male hypogonadism, is related to ichthyosis and male hypogonadism and hypogonadism, male, with mental retardation and skeletal anomalies. An important gene associated with Hypogonadism, Male is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways is Prolactin Signaling Pathway. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and bone marrow, and related phenotypes are male hypogonadism and testicular atrophy

Related Diseases for Hypogonadism, Male

Graphical network of the top 20 diseases related to Hypogonadism, Male:



Diseases related to Hypogonadism, Male

Symptoms & Phenotypes for Hypogonadism, Male

Symptoms via clinical synopsis from OMIM:

57
GU:
male hypogonadism
hypospadias
small penis
normal-sized testes

Misc:
markedly diminished secondary sexual characteristics

Thorax:
gynecomastia


Clinical features from OMIM:

241100

Human phenotypes related to Hypogonadism, Male:

32
# Description HPO Frequency HPO Source Accession
1 male hypogonadism 32 HP:0000026
2 testicular atrophy 32 HP:0000029
3 hypospadias 32 HP:0000047
4 micropenis 32 HP:0000054
5 gynecomastia 32 HP:0000771

GenomeRNAi Phenotypes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.4 BGLAP LEP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.4 BGLAP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.4 BGLAP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.4 LEP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.4 BGLAP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.4 BGLAP
7 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.4 BGLAP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.4 BGLAP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.4 BGLAP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.4 BGLAP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.4 LEP

Drugs & Therapeutics for Hypogonadism, Male

Drugs for Hypogonadism, Male (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
11 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Bone Density Conservation Agents Phase 4
19 Ergocalciferols Phase 4
20 Micronutrients Phase 4
21 Trace Elements Phase 4
22 Vitamins Phase 4
23 insulin Phase 4,Phase 3,Not Applicable
24 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
25 Estradiol 17 beta-cypionate Phase 4
26 Estradiol 3-benzoate Phase 4
27 Follicle Stimulating Hormone Phase 4
28 Calciferol Nutraceutical Phase 4
29 Vitamin D2 Nutraceutical Phase 4
30
Metformin Approved Phase 3 657-24-9 14219 4091
31 Hypoglycemic Agents Phase 3,Not Applicable
32
Dihydrotachysterol Approved Phase 2,Phase 1 67-96-9 5281010 5311071
33
Dutasteride Approved, Investigational Phase 2,Phase 1 164656-23-9 152945 6918296
34
Finasteride Approved Phase 2 98319-26-7 57363
35
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
37 tannic acid Approved, Nutraceutical Phase 1, Phase 2
38
Enclomiphene Investigational Phase 2 15690-57-0
39 Anticoagulants Phase 2
40 Calcium, Dietary Phase 2
41 Chelating Agents Phase 2
42 Clomiphene Phase 2
43 Estrogen Antagonists Phase 2
44 Estrogen Receptor Modulators Phase 2
45 Estrogens Phase 2
46 Fertility Agents Phase 2
47 Selective Estrogen Receptor Modulators Phase 2
48 Zuclomiphene Phase 2
49 5-alpha Reductase Inhibitors Phase 2,Phase 1
50 Steroid Synthesis Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
2 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
3 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
4 Testosterone Replacement in Diabetes With Vascular Disease (Version 2) Completed NCT00355537 Phase 4 Testosterone;0.9% saline
5 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
6 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
7 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
8 Periodontal Profile of Hypogonadic Men Recruiting NCT03176537 Phase 4 Testosterone gel;Placebos
9 Testosterone and Pain Sensitivity Withdrawn NCT01689896 Phase 4 Testosterone Gel;Placebo Gel
10 Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism Unknown status NCT01786473 Phase 3 Testogel 1%;Placebo
11 Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Completed NCT01446042 Phase 3 Testosterone;Testosterone
12 Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). Completed NCT03242590 Phase 3 LPCN 1021
13 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) Completed NCT03242408 Phase 3 LPCN 1021
14 Safety and Efficacy Trial of Testosterone Undecanoate Completed NCT01765179 Phase 3 Oral testosterone undecanoate
15 Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed NCT01403116 Phase 3 oral testosterone undecanoate;topical testosterone gel 1%
16 Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism Completed NCT02081300 Phase 3 Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
17 Time to Eugonadal Range, Time to Steady State and Drying Time Completed NCT01228071 Phase 3 testosterone gel 2%
18 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males Completed NCT02149264 Phase 3 Testosterone gel (FE 999303)
19 A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel Completed NCT01703741 Phase 3 Testosterone Gel (FE 999093)
20 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel Completed NCT01665599 Phase 3 Testosterone gel (FE 999303)
21 Testosterone, Metformin, or Both, for Hypogonadism in Obese Males Completed NCT02514629 Phase 3 Placebo;Metformin;Testosterone Undecanoate;Metformin + Testosterone Undecanoate
22 The Comparison of Diagnostic TESE and TESA in Non-obstructive Azoospermic Completed NCT01210326 Phase 2, Phase 3
23 Open-Label Study of ARD-0403 in Testosterone Deficient Men Completed NCT00448955 Phase 3 ARD-0403
24 Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men Recruiting NCT03198728 Phase 3 SOV2012-F1;AndroGel
25 Open-Label Study of ARD-0403 in Testosterone Deficient Men Terminated NCT00562731 Phase 3 ARD-0403
26 Clomid in Men With Low Testosterone With and Without Prior Treatment Unknown status NCT01904734 Phase 2 Clomiphene
27 Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism Completed NCT02380755 Phase 2 Clomiphene Citrate;Placebo
28 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Completed NCT00398580 Phase 2 Nanomilled testosterone;Nanomilled dutasteride;commercially available dutasteride
29 Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation Completed NCT00924612 Phase 2 Oral testosterone undecanoate (containing 300 mg of T)
30 Efficacy, Pharmacokinetics and Safety of Testosterone Completed NCT01370369 Phase 2 Testosterone gel (FE 99903)
31 Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Completed NCT02777242 Phase 2
32 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride;Testosterone Enanthate;Finasteride
33 Pharmacokinetic Study to Determine Time to Steady-state Completed NCT00911586 Phase 2 Testosterone undecanoate
34 Safety of Testosterone Undecanoate i.m. in Hypogonadal Men Completed NCT00452322 Phase 2 Testosterone Substitution by Testosterone Undecanoate i.m.
35 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Completed NCT02697188 Phase 2 Testosterone undecanoate;Testosterone enanthate
36 Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men Completed NCT00695110 Phase 2 Testosterone undecanoate (TU);TU + testosterone enanthate (TE);Testosterone undecanoate (TU);TU + testosterone enanthate (TE)
37 A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Active, not recruiting NCT03335254 Phase 1, Phase 2 TSX-011
38 Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Completed NCT00400335 Phase 1 Nanomilled testosterone;commercially available dutasteride;Nanomilled dutasteride
39 Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism Recruiting NCT02966652 Phase 1 DITEST;Testosterone undecanoate
40 Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia Unknown status NCT02008799 Not Applicable
41 The Effect of Low Electrical Current on Testicular Spermatocyte Count Unknown status NCT02617173 Not Applicable
42 Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males Completed NCT03541395 Not Applicable GnRH antagonist
43 Registry of Hypogonadism in Men Completed NCT00858650
44 ESPRIT Study in Hypogonadal Men Completed NCT01143818 AndroGel (testosterone gel) 1%
45 Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice Completed NCT00410306 Testosterone Undecanoate (Nebido, BAY86-5037)
46 Older Men and Testosterone Completed NCT00119483 Not Applicable Nebido (Testosterone Undecanoate)
47 Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism Completed NCT00613288 Not Applicable Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
48 Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism Completed NCT02728440 human chorionic gonadotropin, human menopausal gonadotropin
49 Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation Completed NCT02434562
50 Calciotropic Effects After hCG Stimulation Test Recruiting NCT03254641 human chorionic gonadotropin

Search NIH Clinical Center for Hypogonadism, Male

Genetic Tests for Hypogonadism, Male

Genetic tests related to Hypogonadism, Male:

# Genetic test Affiliating Genes
1 Male Hypogonadism 29

Anatomical Context for Hypogonadism, Male

MalaCards organs/tissues related to Hypogonadism, Male:

41
Bone, Testes, Bone Marrow, Endothelial, Prostate, Hypothalamus, Heart

Publications for Hypogonadism, Male

Articles related to Hypogonadism, Male:

(show top 50) (show all 100)
# Title Authors Year
1
Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity. ( 29948931 )
2018
2
Metabolic Syndrome in Male Hypogonadism. ( 29895018 )
2018
3
Novel Therapy for Male Hypogonadism. ( 29886559 )
2018
4
Metabolic patterns in insulin-resistant male hypogonadism. ( 29867095 )
2018
5
Metabolic patterns in insulin-sensitive male hypogonadism. ( 29844353 )
2018
6
The safety of available treatments of male hypogonadism in organic and functional hypogonadism. ( 29334271 )
2018
7
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity. ( 29974886 )
2018
8
Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. ( 29145707 )
2018
9
Approaches to male hypogonadism in primary care. ( 28085783 )
2017
10
Importance of abdominal circumference and body mass index values in predicting male hypogonadism - A practical approach. ( 27598980 )
2016
11
The Role of Estrogen Modulators in Male Hypogonadism and Infertility. ( 27601965 )
2016
12
Emerging medication for the treatment of male hypogonadism. ( 27552127 )
2016
13
Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. ( 27510348 )
2016
14
Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. ( 27581270 )
2016
15
Human Immunodeficiency Virus Infection and Male Hypogonadism: A Review. ( 26638598 )
2015
16
Bone benefits of testosterone replacement therapy in male hypogonadism. ( 24994579 )
2014
17
Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. ( 25384570 )
2014
18
Treatment options for male hypogonadism. ( 23627244 )
2013
19
Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. ( 23258624 )
2013
20
IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. ( 22812645 )
2013
21
Re: circulating endothelial cells as marker of endothelial damage in male hypogonadism. ( 23312191 )
2013
22
Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice. ( 24279472 )
2013
23
Use of biomarkers to assess tissue specific androgen adequacy: defining male hypogonadism. ( 23260553 )
2013
24
Re: IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. ( 23235241 )
2013
25
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and II_BI^ and attenuated by argirein and valsartan. ( 23665494 )
2013
26
Male hypogonadism. ( 24119423 )
2013
27
Selective androgen receptor modulators for the treatment of late onset male hypogonadism. ( 24407183 )
2013
28
Subclinical male hypogonadism. ( 22863395 )
2012
29
Emerging medication for the treatment of male hypogonadism. ( 22612692 )
2012
30
Male hypogonadism at a tertiary care hospital in Karachi, Pakistan. ( 24397056 )
2012
31
Effects of male hypogonadism on regional adipose tissue fatty acid storage and lipogenic proteins. ( 22363653 )
2012
32
High prevalence of male hypogonadism and sexual dysfunction in long-term clinically stable heart transplantation recipients. ( 22251415 )
2012
33
Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism. ( 22277727 )
2012
34
Male hypogonadism: more than just a low testosterone. ( 23027731 )
2012
35
Circulating endothelial cells as marker of endothelial damage in male hypogonadism. ( 22700760 )
2012
36
Topical testosterone supplementation for the treatment of male hypogonadism. ( 22867042 )
2012
37
Enhanced immunological response by dendritic cells in male hypogonadism. ( 22957648 )
2012
38
Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. ( 22341266 )
2012
39
Sertoli cell markers in the diagnosis of paediatric male hypogonadism. ( 22570945 )
2012
40
Late-onset male hypogonadism: clinical and laboratory evaluation. ( 21486896 )
2011
41
Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism. ( 21810381 )
2011
42
A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. ( 21269402 )
2011
43
Statins and male hypogonadism. ( 21492398 )
2011
44
Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. ( 21521164 )
2011
45
Male hypogonadism and germ cell loss caused by a mutation in Polo-like kinase 4. ( 21791561 )
2011
46
New perspectives in the diagnosis of pediatric male hypogonadism: the importance of AMH as a Sertoli cell marker. ( 22218431 )
2011
47
Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. ( 20628262 )
2010
48
Prevalence of undiagnosed testosterone deficiency in aging athletes: does exercise training influence the symptoms of male hypogonadism? ( 20141589 )
2010
49
A practical guide to male hypogonadism in the primary care setting. ( 20518947 )
2010
50
Anti-mA1llerian hormone and sertoli cell function in paediatric male hypogonadism. ( 20190544 )
2010

Variations for Hypogonadism, Male

Expression for Hypogonadism, Male

Search GEO for disease gene expression data for Hypogonadism, Male.

Pathways for Hypogonadism, Male

Pathways related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.08 LEP LHCGR

GO Terms for Hypogonadism, Male

Biological processes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.26 BGLAP LEP
2 response to nutrient levels GO:0031667 9.16 BGLAP LEP
3 response to activity GO:0014823 8.96 BGLAP LEP
4 regulation of osteoclast differentiation GO:0045670 8.62 BGLAP LHCGR

Sources for Hypogonadism, Male

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....